Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children

儿童SARS-CoV-2相关多系统炎症综合征中免疫失调和自身反应性与疾病严重程度相关

阅读:2
作者:Anjali Ramaswamy ,Nina N Brodsky ,Tomokazu S Sumida ,Michela Comi ,Hiromitsu Asashima ,Kenneth B Hoehn ,Ningshan Li ,Yunqing Liu ,Aagam Shah ,Neal G Ravindra ,Jason Bishai ,Alamzeb Khan ,William Lau ,Brian Sellers ,Neha Bansal ,Pamela Guerrerio ,Avraham Unterman ,Victoria Habet ,Andrew J Rice ,Jason Catanzaro ,Harsha Chandnani ,Merrick Lopez ,Naftali Kaminski ,Charles S Dela Cruz ,John S Tsang ,Zuoheng Wang ,Xiting Yan ,Steven H Kleinstein ,David van Dijk ,Richard W Pierce ,David A Hafler ,Carrie L Lucas

Abstract

Multisystem inflammatory syndrome in children (MIS-C) is a life-threatening post-infectious complication occurring unpredictably weeks after mild or asymptomatic SARS-CoV-2 infection. We profiled MIS-C, adult COVID-19, and healthy pediatric and adult individuals using single-cell RNA sequencing, flow cytometry, antigen receptor repertoire analysis, and unbiased serum proteomics, which collectively identified a signature in MIS-C patients that correlated with disease severity. Despite having no evidence of active infection, MIS-C patients had elevated S100A-family alarmins and decreased antigen presentation signatures, indicative of myeloid dysfunction. MIS-C patients showed elevated expression of cytotoxicity genes in NK and CD8+ T cells and expansion of specific IgG-expressing plasmablasts. Clinically severe MIS-C patients displayed skewed memory T cell TCR repertoires and autoimmunity characterized by endothelium-reactive IgG. The alarmin, cytotoxicity, TCR repertoire, and plasmablast signatures we defined have potential for application in the clinic to better diagnose and potentially predict disease severity early in the course of MIS-C.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。